TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.71 USD
+0.09 (5.56%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $1.73 +0.02 (1.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TCRX 1.71 +0.09(5.56%)
Will TCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Other News for TCRX
Tracking Baker Brothers Portfolio - Q1 2025 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)
TScan Therapeutics management to meet virtually with BTIG
TCRX: Upcoming Virtual Meeting Scheduled for May 15 | TCRX Stock News